**AUB KQ1 Evidence Table (Reference ID #1304, #1255)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality****Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**Fraser et al., 1981Fraser et al., 1984a**Country:**Australia**Enrollment** **period:** NR**Intervention** **setting:** NR**Funding:**Park-Davis and CoAustralian National Health and Medical Research council**Author industry relationship disclosures:**NR**Study Design:** RCT (crossover)**Blinding:** Patients, clinicians | **Intervention:**Mefenamic acid500mg, 3 times/day, onset to end of menses for 2 cycles followed by placebo for 2 cycles**Comparator:**Placebo for two cycles followed by mefenamic acid for 2 cycles**Groups:****G1:** Mefenamic acid first then placebo**G2:** Placebo first then mefenamic acid**Ga:** Mefenamic acid**Gb:** Placebo**Followup:**4 cycles | **Inclusion criteria:** Menorrhagia**Exclusion criteria:** See inclusion criteria**N at enrollmenta:** **G1+G2:** 85**N at followup:** **G1:** 38**G2:** 31**Age years, mean ± SD:****G1+G2**: 33 ± 6.9**BMI:**NR**Parity:**NR**Race/ethnicity:**NR  | **Bleeding:**Menorrhagia duration, mean years ± SD:**G1+G2:** 11.2 ± 9.4Dysmenorrhea duration, mean years ± SD: **G1+G2:** 11.6 ± 8.5 Bleeding days per cycle, mean ± SD:**G1+G2:** 3.3 ± 1.8Pain, days per cycle, mean ± SD:**G1:** 3.1 ± 1.9**G2:** 3.1 ± 1.7 | **Bleeding:**MBL measured by alkaline hematin method, mean ml (SE):All patients (n=69): **Ga:** 48.1 (4.4)**Gb:** 66.9 (4.7)**Ga vs. Gb:** p<0.001True menorrhagia (n=30):**Ga:** 77.2 (8.7)**Gb:** 110 (5.9)**Ga vs. Gb:** p<0.001MBL <80 ml (n=39):**Ga:** 36.9 (3.4)**Gb:** 45.8 (2.6)**Ga vs. Gb:** p<0.025MBL <35 ml (n=14):**Ga:** 31.6 (7.9)**Gb:** 24.7 (1.4)**Ga vs. Gb:** p=NSMBL measured by alkaline hematin method, mean ml (SE):**G1a:** 55.2 (4.9)**G1b:** 69.4 (5.5)**G2a:** 63.7 (4.7)**G2b:** 39.8 (4.2)**G1a vs. G1b:** p<0.05**G2a vs. G2b:** p<0.001**G1a vs. G2a:** p<0.02**G1b vs. G2b:** p<0.4Bleeding days per cycle, mean (SE):**Ga:** 4.9 (0.14)**Gb:** 5.3 (0.14)**Ga vs. Gb:** p<0.003**Pain:**Abdominal pain, days per cycle, mean (SE):**Ga:** 1.5 (0.13)**Gb:** 2.1 (0.15)**Ga vs. Gb:** p<0.001Headache, days per cycle, mean (SE):**Ga:** 0.8 (0.14)**Gb:** 1.6 (0.16)**Ga vs. Gb:** p<0.001Nausea, days per cycle, mean (SE):**Ga:** 0.6 (0.09)**Gb:** 0.7 (0.10)**Ga vs. Gb:** p=NSDiarrhea, days per cycle, mean (SE):**Ga:** 0.22 (0.06)**Gb:** 0.45 (0.09)**Ga vs. Gb:** p<0.008Depression, days per cycle, mean ± SD:**Ga:** 0.8 (0.15)**Gb:** 1.1 (0.14)**Ga vs. Gb:** p=NSBreast symptoms, days per cycle, mean (SE):**Ga:** 0.9 (0.13)**Gb:** 1.1 (0.18)**Ga vs. Gb:** p=NS **Quality of life:**NR**Patient satisfaction:**NR**Fertility:**NR**Time to conception:**NR**Additional interventions:**NR | **Overall quality:**Fair**Risk of bias:** Randomization: UnclearAllocation concealment:UnclearSelective reporting:LowBlinding patients/personnel:LowBlinding outcome assessment:LowIncomplete outcome reporting:High/LowOther:**Low** |

**Table Notes:** a Intrauterine device (n=6), fibroids (n=2), and Von Willebrand’s disease (n=1); b Comparison of patients’ subjective assessment of menstrual blood loss (60/69 87%) provided perception data accurate enough for analysis.